Buprenorphine in Neonatal Abstinence Syndrome

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and t...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 103; no. 1; p. 112
Main Author Kraft, Walter K
Format Journal Article
LanguageEnglish
Published United States 01.01.2018
Subjects
Buprenorphine - pharmacology
Drug Dosage Calculations
Humans
Infant, Newborn
Narcotic Antagonists - pharmacology
Neonatal Abstinence Syndrome - drug therapy
Opiate Substitution Treatment - methods
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
ISSN:1532-6535
DOI:10.1002/cpt.930